Press release
High-Grade Glioma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
Explore our latest breakthroughs in High-Grade Glioma Research. Learn more about our innovative pipeline today! @ High-Grade Glioma Pipeline Outlook [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the High-Grade Glioma Pipeline Report
* June 2024:- Eli Lilly and Company- A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy. The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy.
* June 2024:- PhaseII Study of Ribociclib and Everolimus Following Radiotherapy in Pediatric and Young Adult Patients Newly Diagnosed With HGG Including DIPG, Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways. Nationwide Children's Hospital- The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target.
* June 2024:- Plus Therapeutics- This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660mL.
* DelveInsight's High-Grade Glioma pipeline report depicts a robust space with 150+ active players working to develop 150+ pipeline therapies for High-Grade Glioma treatment.
* The leading High-Grade Glioma Companies such as Mateon Therapeutics, BioMimetix, Oblato, Inc, PTC Therapeutics, Lee's Pharmaceutical Limited, Nuvation Bio, Inc., Laminar Pharmaceuticals, Basilea Pharmaceutica, Aadi, LLC, Erimos Pharmaceuticals, and others.
* Promising High-Grade Glioma Therapies such as BMX-001, Temozolomide, DB107-FC, ONC201, LAM561, PVSRIPO, Abemaciclib, and others.
Stay informed about the cutting-edge advancements in High-Grade Glioma Treatments. Download for updates and be a part of the revolution in cancer care @ High-Grade Glioma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
High-Grade Glioma Emerging Drugs Profile
* OT101: Mateon Therapeutics
OT101, a first-in-class RNA therapeutic, is designed to abrogate the immunosuppressive actions of TGF-beta 2. In a completed Phase II clinical study, OT-101 exhibited clinically meaningful single-agent activity and induced durable complete and partial responses in recurrent and refractory adult High-Grade Glioma patients, including adults with GBM. Further development of OT-101 may offer renewed hope for salvage therapy of pediatric DIPG patients who have this rare and fatal disease.
* BMX-001: BioMimetix
BMX-001 is being studied in a phase II randomized trial studying the safety and efficacy of the investigational drug in patients with newly diagnosed High-Grade Glioma patients who are being treated with brain radiation and temozolomide.
* OKN-007: Oblato, Inc.
OKN-007 is being developed by Oblato, Inc for the treatment of High-Grade Glioma. It is currently in phase I/II stage of development.
* PTC596: PTC Therapeutics
PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. PTC596 acts by altering and destroying the BMI1 protein through a process called phosphorylation. PTC596 has potently inhibited BMI1 function in multiple tumor cell lines. In in vitro tests, PTC596 has preferentially targeted chemotherapy resistant cancer stem cells. Specifically, PTC596 preferentially depleted cancer stem cells in assays with tumor cell lines from fibrosarcoma, prostate and colon cancers. Conversely, the cytotoxic chemotherapies carboplatin, temozolomide, methotrexate and indibulin enriched the population of cancer stem cells in this assay. It is currently in phase I stage of development.
Learn more about High-Grade Glioma Drugs opportunities in our groundbreaking High-Grade Glioma Research and development projects @ High-Grade Glioma Unmet Needs [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
High-Grade Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Molecule Type
High-Grade Glioma Products have been categorized under various Molecule types such as
* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
* Product Type
Discover the latest advancements in High-Grade Glioma Treatment by visiting our website. Stay informed about how we're transforming the future of disease @ High-Grade Glioma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the High-Grade Glioma Pipeline Report
* Coverage- Global
* High-Grade Glioma Companies- Mateon Therapeutics, BioMimetix, Oblato, Inc, PTC Therapeutics, Lee's Pharmaceutical Limited, Nuvation Bio, Inc., Laminar Pharmaceuticals, Basilea Pharmaceutica, Aadi, LLC, Erimos Pharmaceuticals, and others.
* High-Grade Glioma Therapies- BMX-001, Temozolomide, DB107-FC, ONC201, LAM561, PVSRIPO, Abemaciclib, and others.
* High-Grade Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* High-Grade Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of High-Grade Glioma Pipeline on our website @ High-Grade Glioma Drugs and Companies [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* High-Grade Glioma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* High-Grade Glioma - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* High-Grade Glioma Collaboration Deals
* Late Stage Products (Phase III)
* OT101: Mateon Therapeutics
* Mid Stage Products (Phase II and Phase I/II)
* BMX-001: BioMimetix
* OKN-007: Oblato, Inc.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* PTC596: PTC Therapeutics
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* High-Grade Glioma Key Companies
* High-Grade Glioma Key Products
* High-Grade Glioma- Unmet Needs
* High-Grade Glioma- Market Drivers and Barriers
* High-Grade Glioma- Future Perspectives and Conclusion
* High-Grade Glioma Analyst Views
* High-Grade Glioma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=highgrade-glioma-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release High-Grade Glioma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here
News-ID: 3557369 • Views: …
More Releases from ABNewswire
The Race for AI Power: Alphabet Inc. (Nasdaq: GOOGL) Intersect Acquisition and V …
In December 2025, Alphabet Inc. (NASDAQ: GOOGL) completed the acquisition of Intersect Power, a U.S. renewable energy developer, in a transaction valued at approximately $4.75 billion, including assumed debt. The deal marked a clear shift in how hyperscalers approach infrastructure for artificial intelligence and cloud computing.
Intersect Power develops utility-scale solar generation, battery storage, energized land, and grid interconnections. Its assets are located near existing and planned hyperscale data centers, particularly…
Contrarian Watch Company Redefines Accessible Luxury with Swiss-Made Timepieces …
As holiday gift-giving reaches its peak, Contrarian Watch Company offers Swiss-made luxury watches that challenge traditional industry pricing. The brand combines precision craftsmanship, bold design, and transparent value for consumers who refuse to pay inflated prices for genuine quality.
In a luxury watch market long dominated by heritage brands trading on exclusivity and premium pricing, Contrarian Watch Company launches with a provocative premise: Swiss-made excellence shouldn't require sacrifice. As consumers navigate…
Revolutionary Red Balloon Method Teaches Authors How to Self-Publish Children's …
trish MICHAEL introduces an innovative online course teaching authors to self-publish children's books using the unique Red Balloon Method, which requires zero upfront financial investment. The comprehensive program provides a step-by-step alternative to traditional publishing platforms, making children's book publishing accessible to authors regardless of their budget.
The children's book publishing industry has long presented a significant financial barrier to aspiring authors, with traditional self-publishing routes requiring substantial upfront investments for…
American Plumbing Heating & Cooling Expands Air Conditioning Services Throughout …
American Plumbing Heating & Cooling expands cooling solutions across Southwest Florida with certified technicians, 24/7 emergency service, and transparent pricing for residential and commercial clients.
Sarasota-based HVAC and plumbing specialist American Plumbing Heating & Cooling has announced an expansion of its comprehensive cooling solutions across Southwest Florida. The locally owned company, operating since 2014, continues to address the growing demand for reliable climate control in one of the nation's hottest regions.
With…
More Releases for Glioma
Glioma Market Growth Opportunities 2025-2034
Market Overview
The Glioma Market is witnessing steady growth as new therapeutic approaches continue to emerge for one of the most aggressive and complex forms of brain tumors. Gliomas originate in glial cells and represent the majority of malignant brain cancers. The increasing global incidence of glioblastoma and other high-grade gliomas, combined with rising awareness, improved diagnostic capability, and expanded research in precision oncology, is driving market demand. Novel immunotherapies, targeted…
Glioma Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Glioma Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances…
Glioma Competitive Landscape 2023 (Updated)
DelveInsight's, "Glioma Competitive Landscape 2023" report provides comprehensive insights about 200+ Glioma companies and 220+ drugs in Glioma Competitive landscape. It covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioma Competitive Landscape Report
• DelveInsight's Glioma report depicts a robust space with 200+ Glioma companies working to develop 220+ pipeline therapies…
Low-Grade Glioma Therapeutics Market - Transforming Futures, Defying Low-Grade G …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Low-Grade Glioma Therapeutics Market.
Low-Grade Glioma Therapeutics Market: https://www.growthplusreports.com/report/lowgrade-glioma-therapeutics-market/9187
The Low-Grade Glioma Therapeutics Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the…
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers…
Glioma pipeline involves 150+ key companies continuously working towards develop …
DelveInsight's, "Glioma Pipeline Insight, 2023," report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioma Pipeline Report
• DelveInsight's glioma pipeline report depicts a…
